Q2 2026 Nephros Inc Earnings Call Transcript
Key Points
- Nephros Inc (NEPH) reported record quarterly revenue of $6 million, a 36% increase year-over-year and a 15% sequential increase.
- Core programmatic product revenue grew by double digits year-over-year, demonstrating a strong recurring revenue foundation.
- Service-only revenue nearly tripled, indicating successful adoption of installation, replacement, and ongoing support services.
- The company achieved its highest quarterly net income and adjusted EBITDA in history, with net income increasing over 400% to $1.2 million.
- Growth was broad-based across multiple channels, including infection control filters, service revenue, and emergency response, rather than relying on a single product or region.
- Nephros Inc (NEPH) received a $600,000 tariff refund, which positively impacted gross margin and cash flow.
- The company remains debt-free with a cash balance of $4.7 million, up from $4 million at the end of the first quarter.
- New product development is progressing, with recent launches addressing PFAS, microplastics, and nanoplastics, which are expected to drive future growth.
- The company's education-led demand strategy, including the Nephros Water Institute, is resonating with customers and generating interest.
- Nephros Inc (NEPH) was added to the Russell Microcap Index, increasing its visibility among investors.
- Gross margin improvement was significantly aided by a one-time tariff refund; excluding this, underlying margin pressure persists.
- The company continues to face a 10% tariff on products, which is expected to impair gross profit margins going forward.
- The weakening of the US dollar against the euro has increased product costs and shipping expenses.
- Rapid growth in service revenue, which carries lower margins than core infection control products, is diluting overall gross margin.
- Net cash provided by operating activities declined to $681,000 in Q2 2026 from $994,000 in the prior year period, due to increases in accounts receivable and inventory.
- For the first half of 2026, the company reported net cash used in operations of $990,000, a significant swing from $1.3 million provided in the prior year.
- New product launches, such as those for microplastics and nanoplastics, have not yet gained significant traction and are not expected to be major revenue drivers for several quarters.
- The number of new customers added during the quarter was modest at 1,724, indicating growth is primarily driven by existing customer expansion rather than new customer acquisition.
- Emergency response revenue, while increased, is inherently volatile and not a reliable component of the long-term growth strategy.
- Research and development expenses increased by 18% due to higher salary costs, and SG&A expenses rose 10% due to increased headcount and commissions, pressuring profitability.
Good afternoon, and welcome to the Nephros, Inc. Second Quarter 2026 Financial Results Conference Call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Mr. Kirin Smith, Investor Relations. Please go ahead.
Thank you, operator, and good afternoon, everyone. This is Kirin Smith with PCG Advisory. Thank you all for participating in Nephros' Second Quarter 2026 Conference Call.
Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros. I encourage you to review Nephros' filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Factors that may affect the company
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
